Movement Disorders

Filter Your Results

 

News

 

Research Agenda Created for Women Living with Parkinson's Disease

Wednesday, April 17, 2019—The Parkinson's Foundation Women and Parkinson’s Initiativeis the first patient-centered action agenda for improving quality of life for women with Parkinson…

Technology Has Potential to Halt Production of Mutated Protein in Huntington’s Disease and Spinocerebellar Ataxia

Monday, April 08, 2019—Early data supports a potential therapy for neurodegenerative diseases such as Huntington’s disease (HD) and spinocerebellar ataxia (SCA) that are caused by trinucleotid…

New Drug Application Resubmitted for Istradefylline for Parkinson’s Disease OFF Periods

Ia

Friday, April 05, 2019—A new drug application has been resubmitted to the Food and Drug Administration (FDA) for istradefylline (KW-6002; Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan). Istradefylline h…

Database of Eye-Tracking Movements Could Aid Diagnosis and Treatment

Wednesday, April 03, 2019—Eye-tracking technology (Brain Health EyeQ; RightEye, Bethesda, MD) that captures data on people’s eye movements has been used to produce a database of 1 billion data po…

Trofinetide Phase 2 Study Shows Safety and Clinically Relevant Improvement for Rett’s Syndrome

Wednesday, March 27, 2019—Positive results from a phase 2 randomized, placebo-controlled clinical trial (NCT02715115) of trofinetide (Acadia Pharmaceuticals, San Diego, CA; Neuren Pharmaceuticals, Melb…

First Patient Enrolled in Phase 3 Study of Troriluzole for Spinocerebellar Ataxia

Friday, March 15, 2019—The first patient has been enrolled in a phase 3 study (NCT03701399) of troriluzole (Biohaven, New Haven, CT) to treat spinocerebellar ataxia (SCA). The primary outcome measur…

Motor Function in Persons with REM Sleep Behavior Disorder Predictive of Conversion to Parkinson’s Disease

Tuesday, March 05, 2019—In a large multicenter study of 1,280 patients diagnosed with rapid eye movement (REM) sleep behavior disorder (RBD), published in Brain, patients’ scores on motor …

Verdiperstat, a Potential Treatment for Multiple System Atrophy, Granted Orphan Drug Status

Wednesday, February 20, 2019—The Food and Drug Administration has granted orphan drug status to verdiperstat (BHV-3241; Biohaven Pharmaceutical, New Haven, CT). Verdiperstat is a novel brain-penetrant mye…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC